This is a working overview of analytical methods, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2026-05-24. Anything still debated is marked as such rather than presented as settled.
AOD9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to a short sequence near the end of the 191-amino-acid hormone, often described as residues 176–191 or a related fragment. Researchers designed it to separate metabolic effects from the growth-promoting actions of full-length growth hormone. Early work in the 1990s explored it as a candidate for weight and lipid disorders. It is not a naturally circulating hormone fragment produced in large amounts.
Laboratory studies have reported that AOD9604 can increase lipolysis and reduce lipid accumulation in fat cells. The precise molecular target remains uncertain, and the compound does not appear to activate the growth hormone receptor in the same way as full-length hGH. Proposed mechanisms include effects on beta-adrenergic signaling and enzymes involved in fatty acid synthesis, but these pathways are not firmly established. Because most evidence comes from cell and animal models, whether the same effects occur in humans is an open question.
Clinical development of AOD9604 included trials in people with obesity, but the results did not lead to approval as a prescription medicine in major markets. Interest later shifted to research settings and to unapproved products marketed for body composition. Regulatory agencies have questioned whether the peptide qualifies as a dietary ingredient, and some have issued warnings about its presence in supplements. Long-term human safety data are limited, and questions about efficacy, dosing, and target populations remain unresolved.
Regulatory bodies have taken different approaches to AOD-9604. It is not approved as a prescription medicine by major agencies such as the U.S. Food and Drug Administration or the European Medicines Agency. In sport, the World Anti-Doping Agency prohibits peptide hormones, growth factors, and related substances, and AOD-9604 has been treated as a prohibited substance. These regulatory decisions reflect concerns about safety, efficacy, and potential misuse rather than proof of benefit.
Research on AOD-9604 also examines how the peptide is measured in biological samples. Analytical methods may include liquid chromatography coupled with mass spectrometry, immunoassays, or both. Detection can be challenging because the peptide is small and may be present at low concentrations. Published methods vary in sensitivity and specificity, so comparative interpretation requires attention to validation details. The presence of related hGH fragments can complicate identification in some matrices.
AOD-9604 has been investigated mainly in the context of body fat and metabolic endpoints. Some early animal and small human studies reported changes in fat mass or lipid markers, but findings were not uniform. Larger, well-controlled trials that would establish efficacy are lacking in the public literature. As a result, claims about weight loss or metabolic benefit remain investigational rather than established. The distinction between a research finding and a proven clinical outcome is central to discussing this peptide.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Derived from C-terminal region of human growth hormone |
| Approximate molecular mass | About 1.8 kDa | Varies with sequence length and counterions |
| Confirmed receptor target | None established | No confirmed growth hormone receptor agonism |
| Reported in vitro activity | Lipolysis stimulation and lipogenesis inhibition | Observed mainly in adipocyte models; human relevance uncertain |
| Regulatory status | Not approved as a drug in major markets | May be treated differently across jurisdictions; not a recognized dietary ingredient in some countries |
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to residues 176-191 of the 191-amino-acid hGH sequence. The fragment is not the full hormone and lacks the receptor-binding region associated with growth and metabolic effects of hGH. Researchers developed it to isolate a specific portion of hGH for study. Its exact sequence and length are often stated in peptide catalogs and patents.
The peptide is frequently described as a growth hormone fragment, although it is chemically distinct from full-length hGH. AOD-9604 contains 16 amino acids and includes two cysteine residues that can form an intramolecular disulfide bond. In solution, this structural feature can influence folding, aggregation, and stability. Published descriptions sometimes call it hGH 176-191 or AOD9604, with spacing and capitalization varying. Such naming differences can complicate literature searches, database entries, and product verification.
Researchers have studied the fragment in cell and animal models to understand its metabolic actions. Some experiments report effects on fat breakdown and fat storage pathways, but the underlying mechanism remains incompletely defined. AOD-9604 does not appear to stimulate the same broad growth hormone receptor signaling as full-length hGH. Whether its observed activities arise from direct receptor interactions or downstream metabolic changes is an open question. Results from different assays are not always consistent.
Development of AOD-9604 began in the 1990s as scientists sought to isolate metabolic effects of growth hormone without its growth-promoting actions. Early laboratory work focused on fat cells and animal models. Several human trials followed, examining changes in body composition and fat mass. Results have been mixed, and the peptide has not progressed to widespread clinical approval. Interest continues in research settings, particularly regarding its mechanism and potential metabolic targets.
Regulatory status varies by country. In the United States, AOD-9604 is not approved as a prescription drug. It is sometimes sold as a research chemical or dietary supplement, though such marketing may fall outside legal frameworks. The World Anti-Doping Agency prohibits its use in sport. Researchers must obtain it through legitimate suppliers and follow institutional rules. Its legal classification continues to evolve as authorities increasingly assess peptide products more broadly.
AOD-9604 is a synthetic peptide whose sequence matches the C-terminal fragment of human growth hormone, specifically residues 176 through 191. This region differs from the full hormone in its receptor interactions. The peptide is not a growth hormone secretagogue and does not bind the growth hormone receptor in the same manner. Researchers have examined it for effects on lipid metabolism, but its exact pharmacological profile remains an active area of study.
Developmental expression patterns of four chemosensory protein genes from the Eastern spruce budworm, Choristoneura fumiferana. Insect Mol Biol. 2005; 14: 289-300. 19. Ma C, Cui S, Tian Z, Zhang Y, Chen G, Gao X, Tian Z, Chen H, Guo J, Zhou Z. OcomCSP12, a chemosensory protein expressed specifically by ovary, mediates reproduction in Ophraella communa (Coleoptera: Chrysomelidae). Front Physiol. 2019; 10: 1290. 20. Picimbon JF, Dietrich K, Breer H, Krieger J. Chemosensory proteins of Locusta migratoria (Orthoptera : Acrididae). Insect Biochem Mol Biol. 2000a; 30: 233-241. 21. Guo W, Wang X, Ma Z, Xue L, Han J, Yu D, Kang L. CSP and Takeout genes modulate the switch between attraction and repulsion during behavioral phase change in the migratory locust. PLoS Genet. 2011; 7: e1001291. 22. Martín-Blázquez R, Chen B, Kang L, Bakkali M. Evolution, expression and association of the chemosensory protein genes with the outbreak phase of the two main pest locusts. Sci Rep. 2018; 7: 6653. 23. Zhu J, Iovinella I, Dani FR, Pelosi P, Wang G. Chemosensory proteins: A versatile binding family. In: Picimbon JF (Ed.), Olfactory Concepts of Insect Control-Alternative to Insecticides. vol. 2 Springer Nature, Switzerland, 2019, pp. 147–169. 24. Liu GX, Yue S, Rajashekar B, Picimbon JF. Expression of chemosensory protein (CSP) structures in Pediculus humanis corporis and Acinetobacter baumannii. SOJ Microbiol Infect Dis. 2019; 7: 1-17. 25. Liu GX, Ma HM, Xie HY, Xuan N, Picimbon JF.
In a separate study of rehabilitative strength training following immobilization, creatine supplementation was associated with increased muscle MRF4 protein expression; however, whether changes in MRF4 directly mediate myonuclear accretion or hypertrophy remains uncertain.
Mike Morasky (born June 14, 1964) is an American composer, visual effects artist, director and programmer. He composed the scores for the Valve games Team Fortress 2, the Left 4 Dead series, Portal 2, Counter-Strike: Global Offensive, Half-Life: Alyx and Counter-Strike 2. He worked on visual effects for the Lord of the Rings and Matrix films, and founded the underground art bands Steel Pole Bath Tub, Milk Cult and DUH.
===== Linear or reticular opacities ===== Acute: Pulmonary edema Chronic: Idiopathic pulmonary fibrosis Connective tissue-associated interstitial lung diseases Asbestosis Sarcoidosis Hypersensitivity pneumonitis Drug-induced lung disease
Sources: en.wikipedia.org
The flag of the East India Company is said to have inspired the Continental Union Flag of 1775, ultimately inspiring the current flag of the United States, as both flags were of the same design. Mysorean rockets were also used in the Battle of Baltimore, and are mentioned in "The Star-Spangled Banner", the national anthem of the United States: And the rockets' red glare, the bombs bursting in air.
=== Other characters === Lonnie Anderson (Josh C. Williams, Luke Edwards, Kristopher Kent Hill) – Crystal's eldest child, born to her deceased husband, Sonny. Art (Dan Butler) – A divorced accountant to whom Roseanne and Jackie sell a motorcycle, and who provides tax services to Lanford Custom Cycle. Bob (John McConnell) – A close friend of Dan's. Dwight (William Sadler) – A buddy of Dan's who appears in the early seasons of Roseanne, who had a crush on Jackie. In The Conners, there is another character named Dwight who Dan appears to be friends with, but the character is not portrayed by William Sadler and might be a different character altogether. Fisher (Matt Roth) – Jackie's former long-time boyfriend, whom Dan ultimately went to jail for assaulting after learning he abused Jackie. Stacey Flagler (Traci Lords) – A waitress at the Lunchbox. George (Joseph Gordon-Levitt) – D.J.'s classmate. Gary Hall (Brian Kerwin) – Jackie's former fiancé. Heather (Heather Matarazzo) – D.J.'s girlfriend. Jimmy Meltrigger (Stephen Dorff) – Becky's former boyfriend from high school. Chip Lang (Jared Rushton) – Becky's former boyfriend from high school. Marla (Morgan Fairchild) – Nancy's girlfriend. Anne-Marie Mitchell (Adilah Barnes) – Roseanne's childhood friend, who is married to one of Dan's poker buddies, Chuckie. She and Chuck have a son, Chuck Jr., who is the same age as Lonnie and Darlene. Chuckie Mitchell (James Pickens Jr.) – Anne-Marie's husband, who occasionally worked with Dan.
For over fifty years, Padre Pio of Pietrelcina reported stigmata which were studied by several 20th-century physicians, whose independence from the Church is not known. The observations were reportedly inexplicable and the wounds never became infected. His wounds healed once, but reappeared. The wounds were examined by Luigi Romanelli, chief physician of the City Hospital of Barletta, for about one year. The physician Angelo Maria Merla noted that the wounds were not tubercular in origin but could not make an official diagnosis without further tests. The surgeon Giorgio Festa, a private practitioner, also examined them in 1920 and 1925. Professor Giuseppe Bastianelli, physician to Pope Benedict XV, examined the wounds, but no report of his examinations was made. Pathologist Amico Bignami of the University of Rome also observed the wounds, describing them as shallow. Festa, who had originally agreed with Bignami, later described the wounds as superficial when covered with a scab. Giorgio Festa noted that "at the edges of the lesions, the skin is perfectly normal and does not show any sign of edema, of penetration, or of redness, even when examined with a good magnifying glass". Alberto Caserta took X-rays of the hands in 1954 and found no abnormality in the bone structure. Giuseppe Sala who worked as a physician for Pio between 1956 and 1968 commented that tests revealed his blood had no signs of abnormality. There were both religious and non-religious critics who accused Padre Pio of faking his stigmata, saying he used carbolic acid to make the wounds.
Sources: en.wikipedia.org
A common pathological cause for a high BMR is fever, since a rise in body temperature increases the rate of cellular metabolic reactions. It is estimated that for every degree Fahrenheit of rise in body temperature, the BMR increases by 7 percent. Thyroid disease also has a marked effect on BMR, since thyroid hormones regulate the rate of cellular metabolism. Hyperthyroidism—in which there is an increase in the production of thyroid hormones—leads to a high BMR, while hypothyroidism—in which thyroid hormones are depleted—causes a low BMR. Prolonged periods of abnormal nutrition cause an adaptive change in BMR; this helps the body to maintain a stable body weight in response to the change in food supply. In prolonged malnutrition, the BMR declines, while in prolonged overnutrition, the BMR is increased. Cancer sometimes causes an increase in BMR, perhaps because the cancer cells that form tumors have a high level of metabolic activity.
Investigators have hypothesized that the PHLPP isoforms may play roles in cancer, for several reasons. First, the genetic loci coding for PHLPP1 and 2 are commonly lost in cancer. The region including PHLPP1, 18q21.33, commonly undergoes loss of heterozygosity (LOH) in colon cancers, while 16q22.3, which includes the PHLPP2 gene, undergoes LOH in breast and ovarian cancers, Wilms tumors, prostate cancer and hepatocellular carcinoma. Second, experimental overexpression of PHLPP in cancer cell lines tends to decrease apoptosis and increase proliferation, and stable colon and glioblastoma cell lines overexpressing PHLPP1 show decreased tumor formation in xenograft models. Recent studies have also shown that Bcr-Abl, the fusion protein responsible for chronic myelogenous leukemia (CML), downregulates PHLPP1 and PHLPP2 levels, and that decreasing PHLPP levels interferes with the efficacy of Bcr-Abl inhibitors, including Gleevec, in CML cell lines. Finally, both Akt and PKC are known to be tumor promoters, suggesting that their negative regulator PHLPP may act as a tumor suppressor.
36. Georgian Med News. 2006 Apr;(133):111-5. Anti-aging peptide bioregulators induce reactivation of chromatin. Lezhava T(1), Monaselidze J, Kadotani T, Dvalishvili N, Buadze T. Author information: (1)Tbilisi State University. The effect of synthetic peptide bioregulators (Epitalon, Livagen and Vilon) on structural and facultative heterochromatin of cultivated lymphocytes have been studied among old (75-88yr.) people. The data obtained indicate that epitalon, livagen and vilon: 1) activate synthetic processes, caused by reactivation of ribosomal genes as a result of deheterochromatinization (decondensation) of nucleolus organizer regions; 2) induce unrolling (deheterochromatinization) of total heterochromatin; 3) release genes repressed by heterochromatinization (condensation) of euchromatic regions forming facultative heterochromatin; 4) epitalon and livagen induce deheterochromatinization (decondensation) of pericentromeric structural heterochromatin of the chromosomes1 and 9. However, vilon does not induce deheterochromatinization of pericentromeric structural heterochromatin. These results indicate that peptide bioregulators Epitalon, Livagen and Vilon cause activation (deheterochromatinization) of chromatin in lymphocytes of old individuals.
=== Pretreatments === If the raw material used in the production of the gelatin is derived from bones, dilute acid solutions are used to remove calcium and other salts. Hot water or several solvents may be used to reduce the fat content, which should not exceed 1% before the main extraction step. If the raw material consists of hides and skin, then size reduction, washing, hair removal, and degreasing are necessary to prepare the materials for the hydrolysis step.
Sources: en.wikipedia.org
AOD9604 is a synthetic peptide based on a C-terminal segment of human growth hormone. It is manufactured by chemical peptide synthesis rather than extracted from human tissue. The sequence is often described as hGH fragment 176–191 or a close variant.
It is not approved as a prescription drug in the United States or the European Union for any indication. Regulatory status can differ by country, and it is often sold as a research chemical or in unapproved products. Such products are not equivalent to an approved medicine.
In the studies reported so far, AOD9604 does not appear to act through the growth hormone receptor and has not shown the typical IGF-1 increase caused by full-length hGH. Human data are limited, so this remains an area of uncertainty. It should not be assumed to have the same effects as hGH.
No. It is not approved as a therapeutic drug by major regulators. It is sold for research purposes in many settings, which is not the same as clinical approval.